1. Wu W.N., Heebner J.B., Streeter A.J., Moyer M.D., Takacs A.R., Doose R.D. Ferraiolo B.L.: Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant, topiramate in healthy men. Pharm. Res., 11, Suppl., S336, 1994.
2. Faught E., Wilder B.J., Ramsay R.E., Reife R.A., Kramer L.D., Pledger G.W.: Topiramate placebocontrolled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology, 46, 1684–1690, 1996.
3. Langtry H.D., Gillis J.C., Davis R.: Topiramate — a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs, 54, 752–972, 1997.
4. Van Ameringen M., Mancini C., Pipe B., Campbell M., Oakman J.: Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J. Clin. Psychiatry, 63, 981–984, 2002.
5. Dursun S.M., Devarajan S.: Clozapine weight gain, plus topiramate weight loss [letter]. Can. J. Psychiatry, 45, 198, 2000.